Compare D R Horton Inc (DHI) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
D R Horton Inc vs Medpace Holdings Inc — how do they compare? D R Horton Inc trades at $134.88 (market cap $37.99B), while Medpace Holdings Inc trades at $612.05 (market cap $16.82B). The key difference: D R Horton Inc is far larger — about 2.3× Medpace Holdings Inc's market cap, and D R Horton Inc pays a 1.33% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold D R Horton Inc for 46 Days and Medpace Holdings Inc for 14 Days on average.
| DHI | MEDP | |
|---|---|---|
Market Cap | $37.99B | $16.82B |
Volume | 2,974,460 | 223,093 |
Sector | Consumer Cyclical | Health |
52-Week High | $167.78 | $630.19 |
52-Week Low | $132.53 | $393.42 |
Typical Hold Time | 46 Days | 14 Days |
Enterprise Value | $43.09B | $16.44B |
Dividend Yield | 1.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DHI trades at $134.88, up 1.2% on the day, with a bearish technical signal and neutral oscillators. The stock has beaten earnings estimates in recent quarters, with a P/E of 12.95 and net income margin of 9.15%. Recent news highlights pressure from rising mortgage rates, with the 30-year fixed rate potentially spiking to 9% according to Selma Hepp on CNBC (2026-09-28), impacting homebuilder sentiment.
The outlook is mixed: strong fundamentals and analyst consensus price target of $156.57 offer upside, but macroeconomic risks from interest rates and housing market weakness pose headwinds. Earnings growth remains a key catalyst, yet affordability concerns could dampen near-term performance.
MEDP trades at $612.05, up 1.29% today, near its consensus price target of $620.44. The stock shows strong profitability with a 17.67% net margin and has beaten earnings estimates for the last three quarters. Technical indicators are neutral overall, with support at $595 and resistance at $612. Recent news highlights CEO stock sales and institutional position changes, while the company prepares to report Q3 2026 results on October 21.
Outlook remains positive given consistent earnings beats and projected revenue growth to $2.8B in 2026. Risks include high valuation multiples (P/E 35.41) and insider selling. Analyst consensus is cautious with 79% hold ratings, suggesting limited near-term upside but solid fundamental support for long-term holders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About D R Horton Inc
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
